FDA Looks to Pilot Projects to Enhance Pharma Track and Trace
The U.S. Food and Drug Administration (FDA) is taking a critical step to further enhance its nascent electronic track and trace system for prescription drugs, which was established as part of the Drug Supply Chain Security Act (DSCSA) of 2013. The DSCSA authorized the FDA to build an electronic, interoperable track and trace system by 2023 to reduce drug diversion and introduction of counterfeit products into the U.S. drug supply chain.[1] As part of the Act, FDA was required
